INVENTIVA (EPA:IVA) Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
Transparency directive : regulatory news
05/07/2024 22:00
source : webdisclosure.com
INVENTIVA 's latest news
17/12/2024 22:00
12/12/2024 22:00
21/11/2024 22:00
20/11/2024 22:00
20/11/2024 22:00
15/11/2024 22:00
30/10/2024 21:00
21/10/2024 14:30
14/10/2024 19:45
31/07/2024 22:00
Other stories
03/01/2025 02:10
02/01/2025 19:28
02/01/2025 20:08
03/01/2025 00:40
02/01/2025 19:40
02/01/2025 16:10
02/01/2025 18:32
02/01/2025 23:30
02/01/2025 14:15
02/01/2025 13:00
02/01/2025 13:59
03/01/2025 01:08
03/01/2025 02:41
02/01/2025 22:14
02/01/2025 13:57
02/01/2025 15:42
02/01/2025 13:04
02/01/2025 19:33
02/01/2025 08:14
02/01/2025 09:00
02/01/2025 15:36
01/01/2025 22:00
02/01/2025 23:00
02/01/2025 19:06
02/01/2025 21:35
03/01/2025 00:22
03/01/2025 01:12
02/01/2025 22:52
02/01/2025 22:38
02/01/2025 13:06
02/01/2025 17:44
02/01/2025 19:09
01/01/2025 20:35
01/01/2025 09:30
02/01/2025 07:55
02/01/2025 18:19
02/01/2025 20:57
02/01/2025 16:16